Multiple sclerosis patients with severe walking disability have clinically meaningful improvements in walking speed with prolonged-release fampridine

被引：0
|
作者：
Hartung, H. P.
Goodman, A.
Putzki, N.
机构：
来源：
JOURNAL OF NEUROLOGY | 2011年 / 258卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：260 / 261
页数：2
相关论文
共 50 条
  • [11] Improved Walking Speed in Prolonged-Release Fampridine Timed Walk Responders May Translate to Improvements in Functional Walking Ability
    van Asch, Paul
    Goodman, Andrew
    NEUROLOGY, 2013, 80
  • [12] Response to Prolonged-Release Fampridine in Multiple Sclerosis Patients with Various Walking-Related MS Symptoms
    Short, Christine
    Putzki, Norman
    Goodman, Andrew
    NEUROLOGY, 2012, 78
  • [13] Sustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study.
    Hobart, J.
    Ziemssen, T.
    Feys, P.
    Linnebank, M.
    Goodman, A.
    Farrell, R.
    Englishby, V.
    McNeill, M.
    Chang, I.
    Mehta, L.
    Elkins, J.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 833 - 834
  • [14] Improved walking speed in prolonged-release fampridine timed-walk responders may translate to improvements in functional walking ability
    van Asch, P.
    JOURNAL OF NEUROLOGY, 2012, 259 : S211 - S212
  • [15] Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in Sweden
    Acosta, Carlos
    Gianinazzi, Mattia
    Dort, Thibaut
    Armstrong, Nigel
    Ryder, Steve
    Lundqvist, Thomas
    Ekelund, Mats
    Lycke, Jan
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 770 - 780
  • [16] Clinically meaningful change of walking assessments in patients with multiple sclerosis treated with PR-fampridine
    Sola-Valls, N.
    Blanco, Y.
    Sepulveda, M.
    Llufriu, S.
    Martinez-Lapiscina, E. H.
    Zubizarreta, I.
    La Puma, D.
    Graus, F.
    Villoslada, P.
    Saiz, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 126 - 126
  • [17] QUALITY OF LIFE AMONG PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH PROLONGED-RELEASE FAMPRIDINE 10 MG TABLETS FOR WALKING IMPAIRMENT
    Liu, Y.
    McNeill, M.
    Lee, A.
    Zhong, J.
    Mehta, L. R.
    VALUE IN HEALTH, 2014, 17 (07) : A401 - A402
  • [18] Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
    Jeremy Hobart
    Tjalf Ziemssen
    Peter Feys
    Michael Linnebank
    Andrew D. Goodman
    Rachel Farrell
    Raymond Hupperts
    Andrew R. Blight
    Veronica Englishby
    Manjit McNeill
    Ih Chang
    Gabriel Lima
    Jacob Elkins
    CNS Drugs, 2019, 33 : 61 - 79
  • [19] Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
    Hobart, Jeremy
    Ziemssen, Tjalf
    Feys, Peter
    Linnebank, Michael
    Goodman, Andrew D.
    Farrell, Rachel
    Hupperts, Raymond
    Blight, Andrew R.
    Englishby, Veronica
    McNeill, Manjit
    Chang, Ih
    Lima, Gabriel
    Elkins, Jacob
    CNS DRUGS, 2019, 33 (01) : 61 - 79
  • [20] Prolonged-release fampridine demonstrates rapid and sustained clinically meaningful improvements in walking ability over 24 weeks: MSWS-12 responders in the ENHANCE study
    Hobart, J.
    Ziemssen, T.
    Feys, P.
    Linnebank, M.
    Goodman, A.
    Farrell, R.
    Hupperts, R.
    Englishby, V.
    McNeill, M.
    Chang, I.
    Lima, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 434 - 435
12345